XOCOVA is the brand name for ensitrelvir. The current FDA label approves it for post-exposure prevention of COVID-19 in adults and adolescents age 12 or older following contact with a person who has COVID-19.
Discover Nao Medical's virtual care solutions for occupational health. From wellness checkups to mental health support, boost productivity with care from anywhere.
XOCOVA is the brand name for ensitrelvir. The current FDA label approves it for post-exposure prevention of COVID-19 in adults and adolescents age 12 or older following contact with a person who has COVID-19. The US indication must be distinguished from uses or approvals in other countries and from treatment of an established infection.
Ensitrelvir blocks a viral protease needed for replication. Preventive treatment may reduce the chance of illness after an exposure but cannot guarantee protection. The labeled start is as soon as possible within 72 hours after contact. A positive test or symptoms changes the clinical question and may require an active-infection treatment pathway.
A clinician reviews the exposure and timing, age, pregnancy status and medicines before prescribing. The label contains contraindications for pregnancy and specified interacting drugs. This is not a general daily prevention program or an approved US long-COVID treatment. Pediatric use below age 12 is not established by this indication.
Provide the contact timeline and any symptoms or test results. The clinician verifies eligibility and interactions and explains the prescription, monitoring and next steps if illness develops. If prescribed, use it exactly as directed. Do not borrow a course, change timing or substitute an online dose plan.
Bring a complete medicine and supplement list and pharmacy contact. Pregnancy status must be verified before treatment for patients who can become pregnant. Discuss contraception and breastfeeding before use, not after starting. Ask the pharmacy about actual supply and dispensing timing.
The label warns of fetal harm and clinically important drug interactions. It directs effective contraception during treatment and for 2 weeks afterward and avoidance of breastfeeding during treatment and for 2 weeks afterward. The clinician must check the full interaction list. Severe COVID-19 symptoms require emergency assessment rather than waiting for preventive medicine.
Follow the testing and symptom-monitoring plan. Contact the clinician if symptoms develop or a test becomes positive. A preventive course does not replace vaccination, appropriate exposure precautions or indicated care for an active infection. Early negative testing cannot prove that the exposure caused no infection.
Confirm the prescribing appointment, pharmacy supply and exact insurance coverage promptly. Dispensing must fit the labeled treatment window; do not wait for a routine booking when a time-sensitive prescription is needed.
Seek evaluation promptly after the exposure: Xocova must be started within 72 hours of contact with a person who has COVID-19 under its U.S. label. Insurance authorization, an appointment delay or pharmacy supply does not extend that window. Contact the prescriber immediately if supply or approval may be late so the clinician can reassess the plan. Do not start it outside the prescribed pathway or assume it treats an existing infection.
Xocova is post-exposure prevention, not immediate protection against every infection. Eligible patients must start within 72 hours of contact with a person who has COVID-19, according to the label. Infection can still occur. New symptoms or a positive test need clinical assessment rather than an assumption that preventive treatment has worked.
Xocova's U.S. indication is post-exposure prevention of COVID-19 in eligible adults and adolescents age 12 or older; it is not labeled to treat an existing positive COVID test or long COVID. If you test positive or develop symptoms, promptly ask a clinician about the appropriate assessment and treatment pathway, especially if you are at higher risk.
Tell the prescriber if you are pregnant, could become pregnant, or are breastfeeding, and give a complete medicine and supplement list. Xocova has important pregnancy restrictions and drug interactions. The label advises against breastfeeding during treatment and for 2 weeks after the last dose. The prescriber must review suitability before treatment; do not stop other medicines on your own.
Choose care according to the problem and how urgently you need help. Urgent care assesses non-emergency illnesses and minor injuries.
